更新版 1-Emergent 与 J&J 就 COVID 疫苗供应交易纠纷达成和解

Reuters07-09

((自动化翻译由路透提供，请见免责声明 )) (第2段增加股份，背景贯穿始终)

路透7月8日 - Emergent BioSolutions 周一称，强生公司已同意支付5,000万美元，以解决与后者COVID-19疫苗生产协议终止有关的索赔。

该公司股价在延时交易中上涨了约2%。

2022年，J&J通知Emergent公司决定终止交易，理由是合同制造商违反了 (link) ，包括未能提供COVID-19疫苗药物物质。

Emergent称，J&J违反了协议，未能购买该公司生产的最低数量的COVID-19疫苗。

根据 2020 年签署的为期五年的协议 (link)，Emergent 将提供合同生产服务，生产用于商业生产的 COVID-19 疫苗药物物质。该协议头两年的价值约为 4.8 亿美元。

由于存在罕见的凝血综合症风险，美国卫生监管机构限制 (link) 在 2022 年使用 J&J 疫苗。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450033439?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-09 05:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2450033439","market":"us","top_or_hot":-1,"title":"更新版 1-Emergent 与 J&J 就 COVID 疫苗供应交易纠纷达成和解","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 )) (第2段增加股份，背景贯穿始终)</p><p>    路透7月8日 - Emergent BioSolutions   周一称，<a href=\"https://laohu8.com/S/JNJ\">强生</a>公司  已同意支付5,000万美元，以解决与后者COVID-19疫苗生产协议终止有关的索赔。 </p><p>该公司股价在延时交易中上涨了约2%。 </p><p>2022年，J&amp;J通知Emergent公司决定终止交易，理由是  合同制造商违反了 (link) ，包括未能提供COVID-19疫苗药物物质。</p><p>     Emergent称，J&amp;J违反了协议，未能购买该公司生产的最低数量的COVID-19疫苗。</p><p> 根据  2020 年签署 的 为期五年的协议 (link)，Emergent 将提供合同生产服务，生产用于商业生产的 COVID-19 疫苗药物物质。该协议头两年的价值约为 4.8 亿美元。</p><p> 由于存在罕见的凝血综合症风险 ， 美国卫生监管机构 限制 (link)  在 2022 年使用 J&amp;J 疫苗 。 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>更新版 1-Emergent 与 J&J 就 COVID 疫苗供应交易纠纷达成和解</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n更新版 1-Emergent 与 J&J 就 COVID 疫苗供应交易纠纷达成和解\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-09 05:51 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 )) (第2段增加股份，背景贯穿始终)    路透7月8日 - Emergent BioSolutions   周一称，强生公司  已同意支付5,000万美元，以解决与后者COVID-19疫苗生产协议终止有关的索赔。 该公司股价在延时交易中上涨了约2%。 2022年，J&J通知Emergent公司决定终止交易，理由是  合同制造商违反了 (link) ，包括...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0795875169.SGD","symbol_name":"JPMorgan Investment Funds - Global Income A (div) SGD-H","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2450033439","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450033439","pubTimestamp":1720475486,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"     路透7月8日 - Emergent BioSolutions   周一称，强生公司  已同意支付5,000万美元，以解决与后者COVID-19疫苗生产协议终止有关的索赔。该公司股价在延时交易中上涨了约2%。2022年，J&J通知Emergent公司决定终止交易，理由是  合同制造商违反了  ，包括未能提供COVID-19疫苗药物物质。Emergent称，J&J违反了协议，未能购买该公司生产的最低数量的COVID-19疫苗。由于存在罕见的凝血综合症风险 ， 美国卫生监管机构 限制   在 2022 年使用 J&J 疫苗 。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4548":"巴美列捷福持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BNTX":"BioNTech SE","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4583":"猴痘概念","BK4532":"文艺复兴科技持仓","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","BK4592":"伊斯兰概念","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","EBS":"Emergent Biosolutions","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4535":"淡马锡持仓","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","BK4559":"巴菲特持仓","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","JNJ":"强生","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","BK4551":"寇图资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD"},"translate_title":"UPDATE 1-Emergent settles dispute with J&J over COVID vaccine supply deal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9,"EBS":0.9,"BNTX":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 )) (第2段增加股份，背景贯穿始终)    路透7月8日 - Emergent BioSolutions   周一称，强生公司  已同意支付5,000万美元，以解决与后者COVID-19疫苗生产协议终止有关的索赔。 该公司股价在延时交易中上涨了约2%。 2022年，J&J通知Emergent公司决定终止交易，理由是  合同制造商违反了 (link) ，包括未能提供COVID-19疫苗药物物质。     Emergent称，J&J违反了协议，未能购买该公司生产的最低数量的COVID-19疫苗。 根据  2020 年签署 的 为期五年的协议 (link)，Emergent 将提供合同生产服务，生产用于商业生产的 COVID-19 疫苗药物物质。该协议头两年的价值约为 4.8 亿美元。 由于存在罕见的凝血综合症风险 ， 美国卫生监管机构 限制 (link)  在 2022 年使用 J&J 疫苗 。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450033439"}